Antinuclear antibodies in patients with psoriatic arthritis treated or not with biologics

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Silvy, Florent ^a   Bertin, Daniel ^a   Bardin, Nathalie ^a,b   Auger, Isabelle ^c   Guzian, Marie Caroline ^a   Mattei, Jean Pierre ^a   Guis, Sandrine ^a   Roudier, Jean ^a,c   Balandraud, Nathalie ^a,c  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^b INSERM   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BLOOD DONOR; BLOOD SAMPLING; CLINICAL ASSESSMENT; CONTROLLED STUDY; DACTYLITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; FRANCE; HUMAN; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREDICTIVE VALUE; PREVALENCE; PSORIATIC ARTHRITIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; ADOLESCENT; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; BLOOD; CASE CONTROL STUDY; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTINUCLEAR; ARTHRITIS, PSORIATIC; BIOLOGICAL PRODUCTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84941991986     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134218     Document Type: Article

References (30)

1. Zeidler H, Amor B. The Assessment in Spondyloarthritis International Society (ASAS) classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general: the spondyloarthritis concept in progress. Ann Rheum Dis. 2011; 70: 1-3. doi: 10.1136/ard.2010.135889 PMID: 21163805
2. Torre Alonso JC. [Use and application in clinical practice of the CASPAR criteria]. Reumatol Clin. 2010; 6 Suppl 1: 18-21. doi: 10.1016/j.reuma.2009.12.002 PMID: 21794748
3. Tillett W, Costa L, Jadon D, Wallis D, Cavill C, McHugh J, et al. The ClASsification for Psoriatic ARthritis (CASPAR) criteria - a retrospective feasibility, sensitivity, and specificity study. J Rheumatol. 2012; 39: 154-156. doi: 10.3899/jrheum.110845 PMID: 22089469
4. Chandran V. Spondyloarthritis: CASPAR criteria in early psoriatic arthritis. Nat Rev Rheumatol. 2012; 8: 503-504. doi: 10.1038/nrrheum.2012.121 PMID: 22825727
5. Bogliolo L, Alpini C, Caporali R, Scirè CA, Moratti R, Montecucco C. Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol. 2005; 32: 511-515. PMID: 15742445
6. Vander Cruyssen B, Hoffman IEA, Zmierczak H, Van den Berghe M, Kruithof E, De Rycke L, et al. Anticitrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis. 2005; 64: 1145-1149. doi: 10.1136/ard.2004.032177 PMID: 15695535
7. Marchesoni A, Lurati A, Desiati F, Rossi V, Battafarano N. Antibodies to cyclic citrullinated peptides in psoriatic arthritis: do classification criteria affect study results? J Rheumatol. 2006; 33: 435; author reply 436-437. PMID: 16465678
8. Caspi D, Anouk M, Golan I, Paran D, Kaufman I, Wigler I, et al. Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis. Arthritis Rheum. 2006; 55: 53-56. doi: 10.1002/art.21691 PMID: 16463412
9. Candia L, Marquez J, Gonzalez C, Santos AM, Londoño J, Valle R, et al. Low frequency of anticyclic citrullinated peptide antibodies in psoriatic arthritis but not in cutaneous psoriasis. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2006; 12: 226-229. doi: 10.1097/rhu.0000242779.73390.51
10. Inanc N, Dalkilic E, Kamali S, Kasapoglu-Günal E, Elbir Y, Direskeneli H, et al. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol. 2007; 26: 17-23. doi: 10.1007/s10067-006-0214-5 PMID: 16538391
11. Ouédraogo D-D, Palazzo E, Nicaise-Roland P, Somogyi N, Grootenboer-Mignot S, Hayem G, et al. Anti-cyclic citrullinated peptide antibodies (CCP2) in patients with psoriatic arthritis. Clin Exp Rheumatol. 2007; 25: 930-931. PMID: 18173933
12. Shibata S, Tada Y, Komine M, Hattori N, Osame S, Kanda N, et al. Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis. J Dermatol Sci. 2009; 53: 34-39. doi: 10.1016/j.jdermsci. 2008.06.008 PMID: 18752933
13. Maejima H, Aki R, Watarai A, Shirai K, Hamada Y, Katsuoka K. Antibodies against cyclic citrullinated peptide in Japanese psoriatic arthritis patients. J Dermatol. 2010; 37: 339-345. doi: 10.1111/j.1346-8138.2010.00814.x PMID: 20507403
14. Dalmády S, Kiss M, Képíró L, Kovács L, Sonkodi G, Kemény L, et al. Higher levels of autoantibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis than in patients with psoriasis vulgaris. Clin Dev Immunol. 2013; 2013: 474028. doi: 10.1155/2013/474028 PMID: 23573111
15. Feletar M, Brockbank JE, Schentag CT, Lapp V, Gladman DD. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis. 2004; 63: 156-161. PMID: 14722204
16. Sellam J, Allanore Y, Batteux F, Deslandre CJ, Weill B, Kahan A. Autoantibody induction in patients with refractory spondyloarthropathy treated with infliximab and methotrexate. Jt Bone Spine Rev Rhum. 2005; 72: 48-52. doi: 10.1016/j.jbspin.2004.03.003
17. Poulalhon N, Begon E, Lebbé C, Lioté F, Lahfa M, Bengoufa D, et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol. 2007; 156: 329-336. doi: 10.1111/j.1365-2133.2006.07639.x PMID: 17223874
18. Bacquet-Deschryver H, Jouen F, Quillard M, Ménard JF, Goëb V, Lequerré T, et al. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J Clin Immunol. 2008; 28: 445-455. doi: 10.1007/s10875-008-9214-3 PMID: 18587633
19. Viana VST, de Carvalho JF, de Moraes JCB, Saad CGS, Ribeiro AC de M, Gonçalves C, et al. Autoantibodies in patients with psoriatic arthritis on anti-TNFα therapy. Rev Bras Reumatol. 2010; 50: 225-234. PMID: 21125159
20. Hoffmann JHO, Hartmann M, Enk AH, Hadaschik EN. Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction. Br J Dermatol. 2011; 165: 1355-1358. doi: 10.1111/j.1365-2133.2011.10555.x PMID: 21801160
21. Saraceno R, Specchio F, Torres T, Nisticò SP, Rizza S, Chimenti S. The role of antinuclear autoantibodies in patients with psoriasis treated with anti-tumor necrosis factor-alpha agents: a retrospective long-term study. J Am Acad Dermatol. 2012; 66: e180-182. doi: 10.1016/j.jaad.2011.06.008 PMID: 22507590
22. Lora V, Bonaguri C, Gisondi P, Sandei F, Battistelli L, Russo A, et al. Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab. Immunol Res. 2013; 56: 382-389. doi: 10. 1007/s12026-013-8410-2 PMID: 23572429
23. Saraceno R, Chimenti MS, Chimenti S. The significance of the development of antinuclear antibodies during infliximab treatment. J Am Acad Dermatol. 2013; 69: 314. doi: 10.1016/j.jaad.2013.03.020
24. Chimenti MS, Spinelli FR, Giunta A, Martinelli F, Saraceno R, Conti F, et al. Emergence of antinuclear antibodies in psoriatic patients treated with infliximab: personal experience and literature review. Drug Dev Res. 2014; 75 Suppl 1: S61-63. doi: 10.1002/ddr.21198 PMID: 25381980
25. Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis. 2010; 69: 1420-1422. doi: 10.1136/ard.2009.127100 PMID: 20511607
26. Brito F de A, Santos SME, Ferreira GA, Pedrosa W, Gradisse J, Costa LC, et al. Detection of antinuclear antibodies by indirect immunofluorescence on HEp-2 cells: setting the appropriate screening dilution for the diagnosis of autoimmune rheumatic diseases. Rev Bras Reumatol. 2014; 54: 13-20. PMID: 24878786
27. Sönnichsen N, Apostoloff G, Apostoloff E, Krell L. [Immunologic and clinical studies on psoriasis]. Dtsch Gesundheitswesen. 1966; 21: 973-978.
28. Johnson SR, Schentag CT, Gladman DD. Autoantibodies in biological agent naive patients with psoriatic arthritis. Ann Rheum Dis. 2005; 64: 770-772. doi: 10.1136/ard.2004.031286 PMID: 15834057
29. Li Q-Z, Karp DR, Quan J, Branch VK, Zhou J, Lian Y, et al. Risk factors for ANA positivity in healthy persons. Arthritis Res Ther. 2011; 13: R38. doi: 10.1186/ar3271 PMID: 21366908
30. Saraceno R, Specchio F, Torres T, Nisticò SP, Rizza S, Chimenti S. The role of antinuclear autoantibodies in patients with psoriasis treated with anti-tumor necrosis factor-alpha agents: a retrospective long-term study. J Am Acad Dermatol. 2012; 66: e180-182. doi: 10.1016/j.jaad.2011.06.008 PMID: 22507590